Preventing and managing exacerbations in COPD - Critical appraisal of the role of tiotropium

International Journal of COPD

Volumn 5, Issue 1, 2010, Pages 41-53

  Tashkin, Donald P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular safety; COPD; Exacerbations; Hospitalization; Tiotropium

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; PREDNISOLONE; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE;

ADD ON THERAPY; AIRWAY; AIRWAY OBSTRUCTION; BLURRED VISION; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; HYPERINFLATION; INCIDENCE; META ANALYSIS; MORBIDITY; MORTALITY; OXYGEN THERAPY; PNEUMONIA; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 77951180205     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/copd.s9443     Document Type: Review

References (66)

1. Rodriguez-Roisin R. Toward a consensus definition of COPD exacerbations. Chest. 2000;117:398S-401S.
2. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
3. Stevenson NJ, Walker PP, Costello RW, et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:1510-1516.
4. Spencer S, Jones PW; GLOBE study group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589-593.
5. Sethi S. Etiology and management of infections in chronic obstructive pulmonary disease. Clin Pulm Med. 1999;6:327-332.
6. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465-471.
7. Fujimoto K, Yasuo M, Urushibata K, et al. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J. 2005;25:640-646.
8. Perera WR, Hurst JR, Wilkinson TMA, et al. Inflammaatory changes, recovery and recurrence at COPD exacerbations. Eur Respir J. 2007;29:527-534.
9. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(Suppl 4):46S-53S.
10. Miravitlles M, Mayordomo C, Artes M, et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med. 1999;93:173-179.
11. Decramer M, Celli B, Kesten S, et al. Effects of tiotropium on outcomes in GOLD stage II COPD: Subgroup analysis from the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) Study. Lancet. 2009;374:1171-1178.
12. O'Reilly JF, Williams AE, Holt K, et al. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J. 2006;15:346-353.
13. Donaldson GC, Wedzicha JA. COPD exacerbations: 1: Epidemiology. Thorax. 2006;61:164-168.
14. Celli B. Roger S. Mitchell lecture: Chronic obstructive pulmonary disease, phenotypes and their clinical relevance. Proc Am Thorac Soc. 2006;3:461-465.
15. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-1422.
16. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698-702.
17. O'Donnell DE, Revill SM, Web KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:770-777.
18. Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J. 2005;26:420-428.
19. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832-840.
20. Tashkin DP, Celli B, Senn S, et al. A four-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359: 1543-1554.
21. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:358-364.
22. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-852.
23. American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD, Version 1.2. www.thoracic.org/go/copd. Accessed April 30, 2008.
24. Adams SG, Melo J, Luther M, et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345-1352.
25. Murata GH, Gorby MS, Chick TW, et al. Treatment of decompensated chronic obstructive pulmonary disease in the emergency department correlation between clinical features and prognosis. Ann Emerg Med. 1991;20:125-129.
26. American Lung Association. Trends in chronic bronchitis and emphysema: morbidity and mortality. December 2007. www.lungusa.org. Accessed April 20, 2008.
27. Patil SP, Krishnan JA, Lechtzin N, et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med. 2003;163:1180-1186.
28. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995;274:1852-1857.
29. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26:234-241.
30. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003. Updated 2008.
31. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotorpium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
32. Beeh KM, Beier J, Buhl R, et al. Efficacy of tiotropium bromide (Spiriva) in patients with chronic obstructive pulmonary disease (COPD) of different severities. Pneumologie. 2006;60:3341-3346.
33. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
34. Dusser D, Braveo M-L, Iacono P, et al. The effect of tiotorpium on exacerbations and airflow in patients with COPD. Eur Respir J. 2008;27:547-555.
35. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med. 2005;143:317-326.
36. Kesten S, Plautz M, Piquette CA, et al. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J. 2007;30:898-906.
37. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J. 2002;19:209-216.
38. Briggs DD Jr, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397-405.
39. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evalulation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999;115:635-641.
40. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19-26.
41. O'Brien A, Russo-Magno P, Karki A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med. 2001;164:365-371.
42. van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166:1358-1363.
43. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
44. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300:2407-2416.
45. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162-166.
46. Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Longterm efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J. 2010;35:287-294.
47. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: randomized trial. Ann Intern Med. 2007;146:545-555.
48. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD. COPD. 2009;6:404-415.
49. Baker WL, Baker EL, Coleman CI. Phamacologic treatments for chronic obstructive pulmonary disease: A mixed-treatment comparison metaanalysis. Pharmacotherapy. 2009;29:891-905.
50. Nomura J, Hosoi T, Okuma Y, et al. The presence and function of muscarinic receptors on human T cells: the involvement in IL-2 and IL-2 receptor systems. Life Sci. 2003;72:2121-2126.
51. Koyama S, Rennard SI, Robbins RA. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol. 1992;262:L466-L471.
52. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30:472-478.
53. Tamaoki J, Chiyotani A, Tagaya E, et al. Effect of long term treatment with oxitropium bromide on airway secretions in chronic bronchitis and diffuse panbronchiolitis. Thorax. 1994;49:545-548.
54. Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743-1748.
55. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptomlimited exercise performance over 8 hr with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-1178.
56. Aaron SK, Ferguson D, Marks GB, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63:122-128.
57. Suissa S, Ernst P, Vandemheen KL, et al. Methodologic issues in therapeutic trials. Eur Respir J. 2008;31:927-933.
58. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:842-846.
59. Slymen D, Ayala G, Arredondo EM, et al. Analytic perspective: a demonstration of modeling count data with an application to physical activity. Epidemiol Perspect Innovations. 2006;3:1-9.
60. Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med. 2006;100:1925-1932.
61. Drescher G, Carnathan B, Imus S, Colice G. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing inpatients with COPD exacerbations decreases bronchodilator costs. Respir Care. 2008;53:1678-1684.
62. Colice GL, Carnathan B, Sung J, et al. A respiratory therapist-directed protocol for managing in-patients with asthma and COPD incorporating a long-acting bronchodilator. J Asthma. 2005;42:29-34.
63. Kerstjens HAM, Bantje TA, Luursema PB, et al. Effects of short-acting bronchodilaters added to maintenance tiotropium therapy. Chest. 2007;132:1493-1499.
64. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA. 2008;300:1439-1450.
65. Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20-30.
66. Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130:1695-1703.